|1.||Wu, Guoqiu: 8 articles (01/2015 - 03/2010)|
|2.||Shen, Zilong: 7 articles (07/2013 - 03/2010)|
|3.||Fan, Xiaobo: 4 articles (01/2015 - 03/2010)|
|4.||Xi, Tao: 4 articles (07/2013 - 03/2010)|
|5.||Wu, Pengpeng: 3 articles (01/2015 - 07/2012)|
|6.||Li, Linxian: 3 articles (04/2011 - 03/2010)|
|7.||Hou, Zheng: 2 articles (10/2013 - 01/2011)|
|8.||Xue, Xiaoyan: 2 articles (10/2013 - 01/2011)|
|9.||Luo, Xiaoxing: 2 articles (10/2013 - 01/2011)|
|10.||Zhou, Ying: 2 articles (10/2013 - 01/2011)|
|1.||Septic Shock (Toxic Shock Syndrome)
03/01/2010 - "The results showed that s-thanatin not only completely bound to the LPS (median effective concentration of 17.5microg/mL) but also improved the survival and reduced the number of inoculated bacteria in a mouse model of septic shock. "
02/01/2011 - "Protective effects of antimicrobial peptide S-thanatin against endotoxic shock in mice introduced by LPS."
03/01/2010 - "Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli."
01/01/2015 - "S-thanatin functionalized liposome potentially targeting on Klebsiella pneumoniae and its application in sepsis mouse model."
04/01/2011 - "S-thanatin in vitro prevents colistin resistance and improves its efficacy in an animal model of Pseudomonas aeruginosa sepsis."
07/01/2010 - "We investigated the efficacy of the peptide s-thanatin alone and in combination with tigecycline in an animal model of sepsis induced by cecal ligation and puncture. "
01/15/2011 - "A-thanatin is highly effective against ESBL-EC in vitro, with MIC values ≤4 μg/mL. It has been confirmed that A-thanatin has little hemolysis and relative high stability in plasma. "
09/01/2010 - "In hemolysis assay, S-thanatin exhibited low hemolytic activity and bacteria selectivity. "
10/01/2013 - "R-thanatin might be considered as a specific drug candidate for treating CoNS infections. "
07/01/2012 - "S-thanatin, a novel antimicrobial peptide with 21 amino acid residues, was proved of significant benefit on therapy of pathogens infection. "
06/01/2012 - "Several other molecules (rBPI, heliomicin and thanatin) are currently under development for various systemic infections (Staphylococcus sp., Aspergillus sp., Candida sp. etc.) and may represent important additions to the anti-infectious therapeutic arsenal."
01/15/2011 - "Because the development of multidrug resistance limits the available therapeutic options, A-thanatin may provide a novel strategy for treating ESBL-EC infection and other infections due to multidrug-resistant bacteria."
06/01/2010 - "It should also be noted that the transformant acquired a sufficient level of resistance to the rice blast fungus, Magnaporthe oryzae, presumably due to the repressive activity of thanatin to its initial stage of infection. "
|5.||Anti-Bacterial Agents (Antibiotics)